



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

January 7, 2026

M/s. BSE Ltd  
Mumbai- 400 001

Scrip Code: **524816**

Dear Sir,

Sub: Clarification/Confirmation on news item appearing in  
"<https://economictimes.indiatimes.com/>"

Ref : Your letter No. L/SURV/ONL/RV/SG/ (2025-2026)/ 120 dated January 7, 2026

With reference to above cited subject, we bring to your notice the following clarification

a) Whether such negotiations/events were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations/events till date.

*The litigation is a continuing one since so many months and the outcome of the litigation is awaiting, upon the outcome of the litigation; it will be informed to the Stock Exchanges in due course of time based on the material impact of the litigation on the financial performance of the Company.*

b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the movement in the trading, if any? Further, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015.

*No, the outcome of the litigation is awaiting*

c) The material impact of this article on the Company

*As of now, no material financial impact of the article on the company.*

The company has been consistently making disclosures to the Stock Exchanges as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 and continues to adhere to the said regulations.

This is for your information.

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer